Response

J Natl Cancer Inst. 2018 Oct 1;110(10):1145. doi: 10.1093/jnci/djy031.

Authors

Ariadna Tibau¹, Consolación Molto¹, Eitan Amir²

Affiliations

¹ Oncology Department, Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, Barcelona, Spain.
² Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, Canada.

PMID: 29529214
DOI: 10.1093/jnci/djy031

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents*
United States
United States Food and Drug Administration

Substances

Antineoplastic Agents